Pioneering ALS researcher Kevin Eggan has a new gig.
After holding a tenured position at Harvard while working at the Broad and playing a founder’s role in launching 3 biotechs, Eggan is taking up a job running early-stage research at BioMarin, the rare disease biotech still feeling the sting of a rejection at the hands of the FDA.
Eggan played a high-profile role in working on stem cell therapies, and is credited with helping spur the launch of Quralis, EnClear and Q-State, drawing in $85 million in investor support along the way. He’s done groundbreaking work on ALS, particularly in building disease models for the ailment, and BioMarin spotlighted his involvement in anti-Tau research that the company is using to build an Alzheimer’s program.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,900+ biopharma pros reading Endpoints daily — and it’s free.
